Antimicrobials as Single and Combination Therapy for Colistin-Resistant *Pseudomonas aeruginosa* at a University Hospital in Thailand

Supanun Pungcharoenkijkul¹,², Jantima Traipattanakul³, Sudaluck Thunyaharn⁴ and Wichai Santimaleeworagun⁵,⁶,*

¹ College of Pharmacotherapy Thailand, Nontaburi 11000, Thailand; supanun.pung@gmail.com
² Department of Pharmacist, Nopparat Rajathanee Hospital, Bangkok 10230, Thailand
³ Division of Infectious Disease, Department of Medicine, Phramongkutklao Hospital, Bangkok 10400, Thailand; Jantima24Job@gmail.com
⁴ Faculty of Medical Technology, Nakhonratchasima College, Nakhon Ratchasima 30000, Thailand; tanmicro@gmail.com
⁵ Department of Pharmacy, Faculty of Pharmacy, Silpakorn University, Nakorn Pathom 73000, Thailand
⁶ Pharmaceutical Initiative for Resistant Bacteria and Infectious Disease Working Group (PIRBIG), Nakorn Pathom 73000, Thailand

* Correspondence: swichai1234@gmail.com; Tel.: +66-3425-580-0

Received: 29 June 2020; Accepted: 31 July 2020; Published: 3 August 2020

**Abstract:** Global infections with colistin-resistant *Pseudomonas aeruginosa* (CoR-PA) are increasing; there are currently very few studies focused on the antimicrobial susceptibility of CoR-PA isolates, and none from Thailand. Here, we investigated the impact of various antimicrobials, alone and in combination, via the in vitro testing of CoR-PA clinical isolates. Eighteen CoR-PA isolates were obtained from patients treated at Phramongkutklao Hospital from January 2010 through June 2019; these were classified into six different clonal types by using the enterobacterial repetitive intergenic consensus (ERIC)-PCR method, with a high prevalence of Group A (27.8%). The antimicrobial susceptibility was determined as the minimal inhibitory concentrations (MICs) using the epilometer-test (E-test) method. The synergistic activities of six antimicrobial combinations were reported via the fractional-inhibitory-concentration index. All CoR-PA isolates were susceptible to amikacin, meropenem, and ceftolozane/tazobactam, but only 5.56% were susceptible to imipenem. In vitro synergistic activities were detected for amikacin with aztreonam, piperacillin/tazobactam, meropenem, and ceftazidime for 16.67%, 11.11%, 11.11%, and 5.55%, respectively. One CoR-PA isolate carried the *bla*<sub>VIM</sub> metallo-β-lactamase gene; none carried *mcr-1* genes or detected plasmid-mediated AmpC β-lactamase or an overproduction of chromosomal AmpC β-lactamase. Seven CoR-PA isolates (38.89%) were capable of biofilm formation. In conclusion, CoR-PA isolates are highly susceptible to antimicrobials; the synergy observed in response to the various agents should be examined in a clinical setting.

**Keywords:** biofilm formation; carbapenemase; *mcr-1*; minimal inhibitory concentration

1. **Introduction**

*Pseudomonas aeruginosa*, a nonfermentative Gram-negative rod-shaped bacterium, is a major cause of nosocomial infections, including those of the respiratory tract, skin, soft tissue, urinary tract, surgical sites, and the bloodstream. Infections are particularly prominent in patients with neutropenia and chronic lung diseases [1]. The global incidence of infections due to multidrug-resistant *P. aeruginosa* (MDR-PA) has been increasing; this includes *P. aeruginosa* strains that are resistant to carbapenem...
(CR-PA), which are particularly difficult to treat. The World Health Organization has listed CR-PA as one of the first-priority pathogens for the investigation and development of both new antibiotics and infection-control strategies [2]. In Thailand, 20% of P. aeruginosa specimens isolated from national hospitals from January to December 2019 were identified as CR-PA [3].

Infections with MDR-PA, including carbapenem-resistant strains, are associated with high rates of mortality, currently estimated at approximately 18–61% [1,4]; a combination antimicrobial treatment against CR-PA has been explored in cases that were resistant to treatment. However, the choice of monotherapy or combination therapy in cases of P. aeruginosa infection remains controversial. Previous studies revealed that the use of combination antimicrobial strategies (notably, those empirically designed), were more effective than monotherapy was for patients with P. aeruginosa infections; this was especially the case for critically ill and neutropenic patients. Additionally, several international consensus guidelines that addressed the optimal use of antimicrobial polymyxins recommended that invasive infections of CR-PA should be treated with combination therapy, regardless of the fact that there were no strong randomized control trials that proved the benefit of antimicrobial combinations in these settings [1,5,6].

Unfortunately, given the increasing use of colistin for the treatment of CR-PA infections, colistin-resistant (CoR) strains of P. aeruginosa have been reported. At this time, colistin-resistant P. aeruginosa (CoR-PA) has been documented only sporadically, but it will most likely become a serious problem in the near future. Data from South Korea, Iran, and Egypt documented the prevalence of CoR-PA at 7.4%, 14.9%, and 21.3%, respectively. Similarly, there are two recent publications that reported the emergence of CoR-PA in southern and central Thailand at rates of 1% and 1.6%, respectively [7–11].

At present, there are very few studies that focus on appropriate antimicrobial regimens to treat CoR-PA; various strategies, including the revival of older antibiotics such as aztreonam, remain attractive possibilities. In this study, we evaluated the in vitro susceptibilities of CoR-PA to various single antimicrobials and combinations of antimicrobials in order to optimize treatment. We also considered mechanisms associated with antimicrobial resistance and the prevalence of biofilm formations among the clinical isolates of CoR-PA.

2. Results

Eighteen clinical specimens of CoR-PA were isolated from various sites during a 10-year period. All CoR-PA strains were resistant to colistin, as shown using the broth-microdilution method (MIC > 16 μg/mL). All CoR-PA isolates were susceptible to amikacin, meropenem, and ceftolozane/tazobactam with minimal inhibitory concentrations (MICs) in the range of 0.75–16, 0.094–1.5, and 0.25–3 μg/mL, respectively. By contrast, only 5.56% of the CoR-PA isolates in our study were susceptible to imipenem, with MICs ranging between 1 and 6 μg/mL. Interestingly, 94.44% of the CoR-PA isolates were susceptible to aztreonam (breakpoint ≤ 8 μg/mL). The MIC range, MIC₅₀, and MIC₉₀ results, in response to piperacillin/tazobactam, ceftazidime, imipenem, meropenem, amikacin, gentamicin, ciprofloxacin, levofloxacin, ceftolozane/tazobactam, and aztreonam, are shown in Table 1.
Table 1. Antimicrobial susceptibilities of colistin-resistant P. aeruginosa.

| Antimicrobial Agents             | MIC Range (µg/mL) | MIC50 (µg/mL) | MIC90 (µg/mL) | Susceptibility (%) |
|---------------------------------|-------------------|--------------|--------------|-------------------|
| Piperacillin/tazobactam         | 1.5–32            | 6            | 16           | 88.89             |
| Ceftazidime                     | 0.25–24           | 1.5          | 4            | 94.44             |
| Imipenem                        | 1–6               | 3            | 6            | 5.56              |
| Meropenem                       | 0.094–1.5         | 0.25         | 1            | 100.00            |
| Amikacin                        | 0.75–16           | 1.5          | 4            | 100.00            |
| Gentamicin                      | 0.25–32           | 2            | 2            | 94.44             |
| Ciprofloxacin                   | 0.0625–8          | 0.125        | 4            | 83.33             |
| Levofloxacin                    | 0.38–2            | 0.75         | 1            | 88.89             |
| Ceftolozane/tazobactam          | 0.25–3            | 0.75         | 1.5          | 100.00            |
| Aztreonam                       | 1–12              | 3            | 4            | 94.44             |
| Colistin                        | >16               | >16          | >16          | 0                 |

Abbreviations: MIC, minimal inhibitory concentration; MIC50, minimal inhibitory concentration required to inhibit the growth of 50% of the isolates; MIC90, minimal inhibitory concentration required to inhibit the growth of 90% of the isolates. Note: the antimicrobial susceptibility and MIC breakpoints are according to Clinical and Laboratory Standards Institute (CLSI), 2020.

An evaluation of the clonal relationships by using the enterobacterial repetitive intergenic consensus (ERIC)-PCR method revealed that the 18 isolates could be classified into six clonal types (A–F). Most strains were classified as clonal type A (n = 5), followed by clonal types B–D (n = 3) and clonal types E and F (n = 2), as shown in Table 2.

The in vitro synergistic activities of antimicrobial combinations, as determined with two E-test strips, are shown in Tables 2 and 3. From the 18 CoR-PA isolates, the synergistic effects were detected for three isolates (16.67%); the most effective combination was amikacin with aztreonam, followed by amikacin with piperacillin/tazobactam and meropenem (11.11%), and amikacin with ceftazidime (5.55%). No synergistic responses were detected with combinations of amikacin with imipenem or amikacin with ceftolozane/tazobactam. Taken together, additive responses were identified when amikacin was supplemented with any one of the beta-lactam class of antibiotics (i.e., piperacillin/tazobactam, ceftazidime, aztreonam, ceftolozane/tazobactam, meropenem, or imipenem). No antagonistic effects were observed in response to any of the evaluated combinations.

We considered the possibility that the CoR-PA phenotype was associated with known resistance genes. One CoR-PA isolate (5.56%) produced metallo-β-lactamase (MBL) and carried the blaVIM gene as determined by multiplex PCR; this CoR-PA isolate also tested positive on the E-test MBL strip (imipenem/imipenem + ethylene diamine tetra-acetic acid (EDTA): Liofilchem, Teramo, Italy), another finding that was indicative of metallo-β-lactamase production. Interestingly, none of the 18 CoR-PA strains carried a mcr-1 gene. For phenotypic AmpC confirmation by cefoxitin-clavulanic acid testing, plasmid-mediated AmpC β-lactamase or an overproduction of chromosomal AmpC β-lactamase were not detected among 18 CoR-PA strains (Table 4).

All CoR-PA isolates were evaluated for their capacity to produce biofilm formations using a microtiter-plate assay. The biofilm formation was classified into three groups according to the measured optical-density (OD) values; most strains were unable to generate biofilms (11 isolates or 61.11%). Of the seven isolates (38.89%) that were capable of biofilm formation, these were classified as moderate (five isolates) and weak (two isolates). All CoR-PA strains in clonal types B and E were capable of biofilm formation, and were classified as moderate and weak, respectively.
Table 2. Clonal relationship and antimicrobial combinations of colistin-resistant *P. aeruginosa*.

| No. | Group | Activity | AMK + PIP/TAZ | AMK + CAZ | AMK + IMP | AMK + MEM | AMK + C/T | AMK + ATM |
|-----|-------|----------|---------------|-----------|-----------|-----------|-----------|-----------|
| 1   | A     | ADD      | 0.88          | 1.33 IND  | 1.15 IND  | 0.83 IND  | 1.75 ADD  | 0.83 ADD  |
| 2   | A     | ADD      | 1.41          | 1.41 IND  | 1.15 IND  | 0.71 ADD  | 1.75 ADD  | 0.71 ADD  |
| 3   | A     | IND      | 1.16          | 1.08 IND  | 1.08 IND  | 0.88 IND  | 1.08 IND  | 0.88 IND  |
| 4   | A     | IND      | 0.62          | 0.58 ADD  | 0.58 ADD  | 0.75 ADD  | 1.08 ADD  | 1.08 ADD  |
| 5   | A     | IND      | 0.88          | 1.35 IND  | 1.35 IND  | 0.63 IND  | 1.35 IND  | 0.63 IND  |
| 6   | B     | SYN      | 0.42          | 0.58 ADD  | 0.58 ADD  | 0.88 IND  | 0.58 IND  | 0.88 IND  |
| 7   | B     | ADD      | 0.63          | 0.58 IND  | 0.58 IND  | 0.63 IND  | 0.58 IND  | 0.63 IND  |
| 8   | B     | IND      | 0.88          | 1.08 IND  | 1.08 IND  | 1.08 IND  | 1.08 IND  | 1.08 IND  |
| 9   | C     | ADD      | 0.75          | 1.25 ADD  | 1.25 ADD  | 1.25 ADD  | 1.25 ADD  | 1.25 ADD  |
| 10  | C     | ADD      | 0.75          | 0.75 ADD  | 0.75 ADD  | 0.75 ADD  | 0.75 ADD  | 0.75 ADD  |
| 11  | C     | ADD      | 0.88          | 1.25 ADD  | 1.25 ADD  | 1.25 ADD  | 1.25 ADD  | 1.25 ADD  |
| 12  | C     | ADD      | 0.62          | 1.25 ADD  | 1.25 ADD  | 1.25 ADD  | 1.25 ADD  | 1.25 ADD  |
| 13  | D     | ADD      | 0.62          | 0.75 IND  | 0.75 IND  | 0.75 IND  | 0.75 IND  | 0.75 IND  |
| 14  | D     | ADD      | 0.88          | 1.66 IND  | 1.66 IND  | 1.66 IND  | 1.66 IND  | 1.66 IND  |
| 15  | D     | ADD      | 0.75          | 1.25 IND  | 1.25 IND  | 1.25 IND  | 1.25 IND  | 1.25 IND  |
| 16  | D     | ADD      | 0.88          | 1.25 IND  | 1.25 IND  | 1.25 IND  | 1.25 IND  | 1.25 IND  |
| 17  | D     | ADD      | 0.88          | 1.25 IND  | 1.25 IND  | 1.25 IND  | 1.25 IND  | 1.25 IND  |
| 18  | D     | ADD      | 0.88          | 1.25 IND  | 1.25 IND  | 1.25 IND  | 1.25 IND  | 1.25 IND  |

Abbreviations: ERIC, enterobacterial repetitive intergenic consensus; PCR, polymerase chain reaction; AMK, amikacin; ATM, aztreonam; CAZ, ceftazidime; C/T, ceftolozane/tazobactam; IMP, imipenem; MEM, meropenem; PIP/TAZ, piperacillin/tazobactam; FICI, fractional-inhibitory-concentration index; SYN, synergistic; ADD, additive; IND, indifferent. Note: ΣFICI were interpreted as $\leq 0.5$, synergistic; $>0.5$–$1.0$, additive; $>1.0$–$4.0$, indifferent; $>4.0$, antagonistic effect.
Table 3. Synergistic activity of the antimicrobial combinations of colistin-resistant *P. aeruginosa*.

| Antimicrobial Combinations | Synergistic n (%) | Additive n (%) | Indifferent n (%) |
|----------------------------|-------------------|----------------|------------------|
| Amikacin + piperacillin/tazobactam | 2 (11.11) | 11 (61.11) | 5 (27.78) |
| Amikacin + ceftazidime | 1 (5.55) | 11 (61.11) | 6 (33.33) |
| Amikacin + imipenem | 0 | 5 (27.78) | 13 (72.22) |
| Amikacin + meropenem | 2 (11.11) | 7 (38.89) | 9 (50.00) |
| Amikacin + ceftolozane/tazobactam | 0 | 9 (50.00) | 9 (50.00) |
| Amikacin + aztreonam | 3 (16.67) | 10 (55.56) | 5 (27.78) |

Note: synergistic, additive, and indifferent were defined by the cumulative fractional-inhibitory-concentration index (ΣFICI).

Table 4. The clonal relationship, presence of metallo-β-lactamase genes and *mcr-1*, AmpC confirmation by cefoxitin-cloxacillin testing, and biofilm formation in colistin-resistant *P. aeruginosa*.

| Resistance Genes | Metallo-β-Lactamase |
|------------------|---------------------|
| Isolate No. | ERIC-PCR Group | IMP | VIM | NDM | *mcr-1* | AmpC Confirmation by Cefoxitin-Cloxacillin Testing | Biofilm Formation |
| 1 | A | X | X | X | X | X | No |
| 2 | A | X | X | X | X | X | No |
| 3 | A | X | X | X | X | X | No |
| 4 | A | X | X | X | X | X | No |
| 5 | A | X | X | X | X | X | No |
| 6 | B | X | X | X | X | Moderate | Moderate |
| 7 | B | X | X | X | X | Moderate | Moderate |
| 8 | B | X | X | X | X | Moderate | Moderate |
| 9 | C | X | X | X | X | X | No |
| 10 | C | X | X | X | X | X | No |
| 11 | C | X | X | X | X | X | No |
| 12 | D | X | X | X | X | X | No |
| 13 | D | X | X | X | X | X | Moderate |
| 14 | D | X | X | X | X | X | Moderate |
| 15 | E | X | √ | X | X | X | Weak |
| 16 | E | X | X | X | X | Weak | Weak |
| 17 | F | X | X | X | X | X | No |
| 18 | F | X | X | X | X | X | No |

Abbreviations: ERIC, enterobacterial repetitive intergenic consensus; PCR, polymerase chain reaction. Notes: √, target gene present; X, target gene absent.

3. Discussion

The antimicrobial agent colistin is currently used only as a last resort for the treatment of multidrug-resistant (including carbapenem-resistant) *P. aeruginosa* infections, as it is well-known for having excellent bactericidal activity [12]. Unfortunately, colistin-resistant *P. aeruginosa* strains have been identified in various parts of the world, including Thailand; as such, it was critical to focus this study on CoR-PA bacterial strains. This is the first study in Thailand that explored in vitro antimicrobial susceptibilities, and the first study to ever examine the activities of specific antimicrobial combinations against CoR-PA strains. In this study, we identified colistin-resistant strains using the broth-microdilution method; in previous studies, this was typically performed using disk-diffusion, E-test, and agar-dilution methods [11,13–16].

Previous studies that featured in vitro antimicrobial activity against CoR-PA strains demonstrated a wide range of antimicrobial susceptibilities. For example, Abd El-Baky et al. [11] evaluated the in vitro antimicrobial susceptibility of CoR-PA strains isolated in Egypt; among their findings, most of the CoR-PA strains studied were resistant to cefepime, ceftazidime, and aztreonam, although 80% remained susceptible to meropenem, imipenem, piperacillin, and ciprofloxacin. In another study, Azimi et al. [16] found that all CoR-PA strains in their study were resistant to aztreonam, and most were resistant to other antimicrobial agents as well. However, they found that more than 90% of CoR-PA strains were susceptible to piperacillin/tazobactam, ciprofloxacin, and levofloxacin. These
results can be compared to those presented in our study, in which we show that all CoR-PA strains isolated at our hospital in Thailand were susceptible to most of the evaluated antimicrobial agents.

Aztreonam was first identified in 1981; it is a synthetic monocyclic β-lactam antimicrobial agent that belongs to the family known as monobactams. Aztreonam has a broad spectrum of antimicrobial activity against Gram-negative aerobic bacteria, including Enterobacteriaceae and P. aeruginosa, but has no activity against Gram-positive or anaerobic bacteria. Earlier studies revealed that aztreonam is highly effective when used against Gram-negative bacteria, especially strains of P. aeruginosa [17–19]. Our results revealed that 94.44% of our CoR-PA isolates were susceptible to aztreonam with MICs of ≤8 µg/mL; only one strain was not susceptible, with an MIC of 12 µg/mL. These findings are similar to those previously reported by Mataseje et al. [15], and different to those reported by Abd El-Baky et al. [11] and Azimi et al. [11,16].

We also found that all CoR-PA strains were susceptible to ceftolozane/tazobactam (MIC range, MIC50, and MIC90 at 0.25–3, 0.75, and 1.5 µg/mL, respectively). This antibiotic formulation included a new cephalosporin and β-lactamase inhibitor combination and demonstrated strong activity against MDR strains of P. aeruginosa [20]. As such, as colistin resistance emerges, ceftolozane/tazobactam may be considered as a feasible treatment option for patients infected with CoR-PA. Testing of its efficacy in vivo is needed to confirm these findings.

To the best of our knowledge, this is the first study carried out in Thailand and globally that has identified in vitro synergistic activities in response to combinations of amikacin and aztreonam for CoR-PA strains; previous studies have examined the synergistic effects of aztreonam and amikacin against susceptible strains of P. aeruginosa [21,22]. Synergistic and additive effects associated with the combination of amikacin and aztreonam were observed in clonal types F and A of CoR-PA, respectively; as such, this combination may be among potential treatment options for CoR-PA infections, although studies that explore their in vivo efficacy are needed. Moreover, our study revealed an in vitro synergistic effect of amikacin and piperacillin/tazobactam against 11.11% of the CoR-PA strains. This degree of synergy was less than those identified in previous studies [23–25]; among the strains featured here, this antimicrobial combination primarily promoted additive effects with no observed antagonism. As aztreonam is currently unavailable in Thailand, the combination of amikacin and piperacillin/tazobactam is the best treatment available at this time for infections caused by CoR-PA strains; as noted above, further in vivo studies are needed.

Currently, the resistant mechanisms of colistin in P. aeruginosa are not entirely understood. Modifications or losses of the lipopolysaccharide (LPS) result in the reduction of colistin’s affinity to LPS. Additionally, the overexpression of efflux pumps, such as MexAB-OprM and MexXY-OprM, and a plasmid-mediated mcr-1 gene, was reported in CoR-PA. However, none of the CoR-PA strains in our study carried the mcr-1 gene. These results differed from previous reports in which CoR-PA strains were mcr-1-positive [11,14,26]. Moreover, we did not explore LPS modification or loss, or the overexpression of efflux pumps. Therefore, further study of the mechanisms of colistin resistance in our CoR-PA isolates is needed.

Surprisingly, we identified one CoR-PA isolate that carried the blavIM gene and produced metallo-β-lactamase; this strain was not susceptible to imipenem (MIC at 3 µg/mL), and was resistant to ceftazidime (MIC at 24 µg/mL), but was susceptible to piperacillin/tazobactam, ceftolozane/tazobactam, and meropenem, with MICs at 16, 0.38, and 1 µg/mL, respectively. These findings differed from those previously reported, in which all CoR-PA strains carried the NDM-1 gene and were reported to be resistant to carbapenem [15].

In this study, we found that 38.89% of the CoR-PA isolates were capable of forming biofilms. Biofilm-associated infections are typically difficult to treat and may require higher doses or combinations of antibiotics. Management of these patients might also include the removal of foreign material, especially in cases where device-related infections are suspected.

Our study has some limitations. First, we collected only 18 CoR-PA strains that were amassed over a 10-year period from an area of very low prevalence. Second, our study only evaluated in vitro
susceptibilities; we did not examine optimal dosage regimens and clinical outcomes associated with CoR-PA infections in patients. Additional studies are required to more effectively assess the benefits of these novel treatments, and for the development of novel and efficacious antibiotics to be used to treat CoR-PA infections.

4. Materials and Methods

4.1. Bacterial Isolates

All CoR-PA strains were isolated from patients admitted to Phramongkutklao Hospital, a university hospital in Bangkok, Thailand between January 2010 and June 2019. The CoR-PA isolates were cultured and identified on the basis of their colony characteristics in blood agar; additional differentiation was performed using MacConkey agar (HiMedia, Mumbai, India) and cetrimide agar (Difco, Detroit, MI, USA), accompanied by standard biochemical testing. All CoR-PA strains had MICs of ≥ 4 µg/mL for colistin, as determined using a broth-microdilution kit (Compact Antimicrobial Susceptibility Panel; ComASP) according to the standards provided by the Clinical and Laboratory Standards Institute (CLSI), 2020 version [27].

4.2. Antimicrobial-Susceptibility Testing and Synergistic Activity

All clinical CoR-PA isolates were evaluated on their antimicrobial susceptibility by determining the minimal inhibitory concentration (MIC) values using E-test strips (Liofilchem, Teramo, Italy). The antimicrobials used in this study were piperacillin/tazobactam, ceftazidime, imipenem, meropenem, amikacin, gentamicin, ciprofloxacin, levofloxacin, ceftolozane/tazobactam, and aztreonam. The standard P. aeruginosa strain, ATCC 27853, was used as a control as per CLSI recommendations. The antimicrobial-susceptibility rates were determined from breakpoints of the MIC susceptibility for each antimicrobial agent according to the CLSI criteria [27]. This study also reported the MIC range, MIC$_{50}$, and MIC$_{90}$ of each antimicrobial agent for all isolates under evaluation.

The in vitro synergistic activities of specific antimicrobial combinations were determined by the E-test method. Briefly, the E-test consisted of placing two E-test strips on Mueller–Hinton agar (HiMedia, Mumbai, India) plates with bacteria spread at a 90° angle in cross-formation at the intersection between the MIC values determined for each antimicrobial agent. The six antimicrobial combinations were amikacin with one of the other agents under evaluation, namely, piperacillin/tazobactam, ceftazidime, ceftolozane/tazobactam, imipenem, meropenem, and aztreonam. The cumulative fractional-inhibitory-concentration index (ΣFICI) value of each combination was calculated. ΣFICI values calculated at ≤0.5, >0.5–1.0, >1.0–4.0, and >4.0 were interpreted as synergistic, additive, indifferent, and antagonistic effects, respectively.

4.3. Determination of Clonal Relationships

The clonal relationships between the CoR-PA isolates featured in this study were determined using the ERIC-PCR method. Genomic DNA from all CoR-PA strains was extracted using a commercial kit (Thermo Fisher Scientific, Waltham, MA, USA). The PCR reaction mixture was as previously described [28,29], and used an ERIC forward primer 5’-ATGTAAGCTCTTGAGGGATTAC-3’, and ERIC reverse primer 5’-AAGTAAGGTGACTGGGCTGACGG-3’ for PCR amplification. Thermocycling was performed in a Biometra-TGradient Thermocycler (Biometra, Gottingen, Germany) as follows: 95 °C for 2.5 min, followed by 35 cycles of 46 °C for 30 s, 49 °C for 30 s, 72 °C for 3 min, and lastly, 72 °C for 10 min.

ERIC-PCR products were evaluated via 1.5% agarose-gel (Amresco, Solon, OH, USA) electrophoresis, and stained with ethidium bromide (Bio-Basic, Markham, Ontario, Canada). The classification groups used to differentiate between clonal types included patterns that differed with respect to three or more amplification products.
4.4. Detection of Metallo-β-Lactamase Genes and mcr-1

The PCR reaction mixture and primers used for the detection of metallo-β-lactamase genes were detected by multiplex PCR as previously described and with the primers listed in Table 5 [30]. PCR conditions were as follows: 94 °C for 3 min, 35 cycles of 94 °C for 30 s, 57 °C for 35 s, and 72 °C for 45 s, followed by a final elongation step at 72 °C for 5 min. The PCR reaction mixture and specific primers for mcr-1 (305 bp) detection were as previously described [31,32], using mcr-1-forward primer 5’-CGGTCAGTCCGTTTGTTC-3’ and mcr-1-reverse primer 5’-CTTGGTCGGTCTGTAGGG-3’. PCR conditions were 94 °C for 3 min, followed by 35 cycles of 94 °C for 30 s, 53 °C for 35 s, 72 °C for 45 s, and a final elongation step at 72 °C for 5 min.

Table 5. Primer sequence used to identify metallo-β-lactamase genes.

| Target Gene | Primer Sequence (5′-3′) Amplicon Size (bp) |
|-------------|-------------------------------------------|
| IMP         | Forward GGAATAGAGTGCTTAAAYTCTC          | 232 |
|             | Reverse GGTITAYAAAAACAACCAC              |     |
| VIM         | Forward GATGGTGTTTGGTCGCCATA            | 390 |
|             | Reverse CGAATGCGCAGCACCAC               |     |
| NDM         | Forward GGGTTGCCGATCTGTTTTC             | 621 |
|             | Reverse CGGAATGGCTCATCACGTAC           |     |

All PCR products were evaluated by 1% agarose-gel electrophoresis (Amresco) stained with ethidium bromide. Results were compared with amplicons of known metallo-β-lactamases and mcr-1 genes that were used as positive controls.

4.5. Phenotypic AmpC Confirmation by Cefoxitin-Cloxacillin Testing

The cefoxitin-cloxacillin disk-diffusion test was performed to detect a chromosomal AmpC β-lactamase overproduction or presence of plasmid-mediated AmpC, using the cefoxitin-cloxacillin disk-diffusion test as previously described [33]. Briefly, cefoxitin (30 µg) disks were placed on Mueller–Hinton agar (HiMedia, Mumbai, India), and plates were inoculated with CoR-PA strains with and without 200 µg cloxacillin. The diameters of the cefoxitin-associated clearance zones were evaluated both in the presence and absence of cloxacillin. Differences in inhibition zones greater than 4 mm were considered to be positive for this detection.

4.6. Detection of Biofilm Formation by Microtiter-Plate Assay

All CoR-PA isolates featured in this study were evaluated on their capacity to support biofilm formation using a microtiter-plate assay as previously described [34–36]. Briefly, CoR-PA isolates were adjusted to the 0.5 McFarland standard (1 × 10⁸ cfu/mL); 20 µL of CoR-PA isolates were grown in 96-well flat-bottomed sterile plates with 180 µL of Mueller–Hinton broth II (Difco, Detroit, MI, USA) supplemented with 1% glucose. Plates were incubated at 37 °C for 24 h. Wells were then rinsed with phosphate-buffered saline (PBS), and dry plates were fixed with 150 µL of methanol for 20 min and then stained with 0.1% Crystal Violet for 10–12 min. Plates were then washed with water, and the stain was solubilized in ethanol. Biofilm formation was evaluated as OD₅₅₀ (optical-density at 550 nm) values determined by spectrophotometry. All experiments were performed in triplicate. The results of biofilm formation were interpreted as no, weak, moderate, or strong biofilm production as previously described by Kirmusaoğlu et al. [34].

4.7. Ethical Approval

This study was approved by the ethics review committee of the Institutional Review Board, Royal Thai Army Medical Department, Bangkok, Thailand (approval no. Q019b/62_Exp).
5. Conclusions

The results of our study indicated that clinical isolates of CoR-PA from our hospital were highly susceptible to numerous antimicrobial agents. We identified synergistic antimicrobial activity in response to amikacin combined with aztreonam, piperacillin/tazobactam, meropenem, and ceftazidime in studies performed in vitro. These combinations may emerge as potential treatment options for severe infections associated with infections with CoR-PA strains. Additional studies are needed to determine the overall efficacy and clinical outcomes. Several of these CoR-PA clinical isolates were also capable of forming biofilms. This point should be considered with respect to ongoing patient-management issues. In addition to antimicrobial therapy, it is important to consider the removal of foreign material if device-related infections are suspected.

Author Contributions: Conceptualization, W.S. and S.P.; methodology, W.S., J.T., and S.T.; software, W.S.; validation, S.P.; formal analysis, W.S. and S.P.; investigation, W.S. and S.P.; resources, W.S., J.T., and S.T.; data curation, W.S. and S.P.; writing—original draft preparation, S.P.; writing—review and editing, W.S., J.T., and S.T.; visualization, W.S. and S.P.; supervision, W.S.; project administration, W.S.; funding acquisition, W.S and S.P. All authors have read and agreed to the published version of the manuscript.

Funding: This research was funded by Doctor Kasem Pangsrivongse Foundation and Faculty of Pharmacy, Silpakorn University. The funders had no role in the design of the study; in the collection, analyses, or interpretation of data; in the writing of the manuscript, and in the decision to publish the results.

Conflicts of Interest: The authors declare no conflict of interest.

References

1. Ramphal, R. Infectious Disease to Psudomonas, Burkholderia, and Stenotrophomonas Species. In Harison’s Principles of Internal Medicine, 20th ed.; Jameson, J.L., Kasper, D.L., Longo, D.L., Fauci, A.S., Hauser, S.L., Loscalzo, J., Eds.; McGraw-Hill Education: New York, NY, USA, 2018; Volume 1, pp. 1167–1173.

2. World Health Organization. WHO Publishes List of Bacteria for Which New Antibiotics Are Urgently Needed. WHO Department of Communications. Available online: https://www.who.int/news-room/detail/27-02-2017-who-publishes-list-of-bacteria-for-which-new-antibiotics-are-urgently-needed (accessed on 18 April 2020).

3. National Antimicrobial Resistance Surveillance Center. Thailand. Available online: http://narst.dmsc.moph.go.th/ (accessed on 18 April 2020).

4. Lin, K.Y.; Lauderdale, T.L.; Wang, J.T.; Chang, S.C. Carbapenem-resistant Pseudomonas aeruginosa in Taiwan: Prevalence, risk factors, and impact on outcome of infections. J. Microbiol. Immunol. Infect. 2016, 49, 52–59. [CrossRef] [PubMed]

5. Tang, S.Y.; Zhang, S.W.; Wu, J.D.; Wu, F.; Zhang, J.; Dong, J.T.; Guo, P.; Zhang, D.L.; Yang, J.T.; Zhang, W.J. Comparison of mono- and combination antibiotic therapy for the treatment of Pseudomonas aeruginosa bacteraemia: A cumulative meta-analysis of cohort studies. Exp. Ther. Med. 2018, 15, 2418–2428. [PubMed]

6. Tsuji, B.T.; Pogue, J.M.; Zavascki, A.P.; Paul, M.; Daikos, G.L.; Forrest, A.; Giacobbe, D.R.; Viscoli, C.; Giamarellou, H.; Karaiskos, I.; et al. International Consensus Guidelines for the Optimal Use of the Polymyxins: Endorsed by the American College of Clinical Pharmacy (ACCP), European Society of Clinical Microbiology and Infectious Diseases (ESCMID), Infectious Diseases Society of America (IDSA), International Society for Anti-infective Pharmacology (ISAP), Society of Critical Care Medicine (SCCM), and Society of Infectious Diseases Pharmacists (SIDP). Pharmacotherapy 2019, 39, 10–39. [PubMed]

7. Tunyapanit, W.; Pruekprasert, P.; Laoprasopwattana, K.; Chelae, S. In vitro activity of colistin against multidrug-resistant Pseudomonas aeruginosa isolates from patients in Songklanagarind Hospital, Thailand. Southeast Asian J. Trop. Med. Public Health 2013, 44, 273–280.

8. Santimealeeworagun, W.; Thunyaharn, S.; Juntanawiwat, P.; Thongnoy, N.; Harindhanavudhi, S.; Nakeesathit, S.; Teschumroon, S. The prevalence of colistin-resistant Gram-negative bacteria isolated from hospitalized patients with bacteremia. J. Appl. Pharm. Sci. 2020, 10, 056–059.

9. Wi, Y.M.; Choi, J.Y.; Lee, J.Y.; Kang, C.I.; Chung, D.R.; Peck, K.R.; Song, J.H.; Ko, K.S. Emergence of colistin resistance in Pseudomonas aeruginosa ST235 clone in South Korea. Int. J. Antimicrob. Agents 2017, 49, 767–769. [CrossRef]
10. Yousefi, S.; Nahaei, M.R.; Farajnia, S.; Aghazadeh, M.; Iversen, A.; Edquist, P.; Maáíallah, M.; Giske, C.G. A multiresistant clone of *Pseudomonas aeruginosa* sequence type 773 spreading in a burn unit in Orumieh, Iran. *Apmis* 2013, 121, 146–152. [CrossRef]

11. Abd El-Baky, R.M.; Masoud, S.M.; Mohamed, D.S.; Waly, N.G.; Shafik, E.A.; Mohareb, D.A.; Elkady, A.; Elbadr, M.M.; Hetta, H.F. Prevalence and Some Possible Mechanisms of Colistin Resistance Among Multidrug-Resistant and Extensively Drug-Resistant *Pseudomonas aeruginosa*. *Infect. Drug Resist.* 2020, 13, 323–332. [CrossRef]

12. Falagas, M.E.; Kasiakou, S.K. Colistin: The revival of polymyxins for the management of multidrug-resistant gram-negative bacterial infections. *Clin. Infect. Dis.* 2005, 40, 1333–1341. [CrossRef]

13. Samonis, G.; Matthaiou, D.K.; Kofteridis, D.; Maraki, S.; Falagas, M.E. In vitro susceptibility to various antibiotics of colistin-resistant gram-negative bacterial isolates in a general tertiary hospital in Crete, Greece. *Clin. Infect. Dis.* 2010, 50, 1689–1691. [CrossRef] [PubMed]

14. Goli, H.R.; Nahaei, M.R.; Ahangarzadeh Rezaee, M.; Hasani, A.; Samadi Kafil, H.; Aghazadeh, M. Emergence of colistin resistant *Pseudomonas aeruginosa* at Tabriz hospitals, Iran. *Iran. J. Microbiol.* 2016, 8, 62–69. [PubMed]

15. Mataseje, L.F.; Peirano, G.; Church, D.L.; Conly, J.; Mulvey, M.; Pitout, J.D. Colistin-Nonsusceptible *Pseudomonas aeruginosa* Sequence Type 654 with *bla* _NDM-1_ Arrives in North America. *Antimicrob. Agents Chemother.* 2016, 60, 1794–1800. [CrossRef]

16. Azimi, L.; Lari, A.R. Colistin-resistant *Pseudomonas aeruginosa* clinical strains with defective biofilm formation. *GMS Hyg. Infect. Control* 2019, 14. [CrossRef]

17. Sykes, R.B.; Bonner, D.P.; Bush, K.; Georgopapadakou, N.H. Aztreonam (SQ 26,776), a synthetic monobactam specifically active against aerobic gram-negative bacteria. *Antimicrob. Agents Chemother.* 1982, 21, 85–92. [CrossRef] [PubMed]

18. Barry, A.L.; Thornsberry, C.; Jones, R.N.; Gavan, T.L. Aztreonam: Antibacterial activity, beta-lactamase stability, and interpretive standards and quality control guidelines for disk-diffusion susceptibility tests. *Rev. Infect. Dis.* 1985, 7, S594–S604. [CrossRef] [PubMed]

19. Sykes, R.B.; Bonner, D.P. Discovery and development of the monobactams. *Rev. Infect. Dis.* 1985, 7, S579–S593. [CrossRef]

20. Zhanel, G.G.; Chung, P.; Adam, H.; Zelenitsky, S.; Denisuik, A.; Schweizer, F.; Lagacé-Wiens, P.R.; Rubinstein, E.; Gin, A.S.; Walkty, A.; et al. Ceftolozane/tazobactam: A novel cephalosporin/β-lactamase inhibitor combination with activity against multidrug-resistant gram-negative bacilli. *Drugs* 2014, 74, 31–51. [CrossRef]

21. Buesing, M.A.; Jorgensen, J.H. In vitro activity of aztreonam in combination with newer beta-lactams and amikacin against multiply resistant gram-negative bacilli. *Antimicrob. Agents Chemother.* 1984, 25, 283–285. [CrossRef]

22. Brogden, R.N.; Heel, R.C. Aztreonam. A review of its antibacterial activity, pharmacokinetic properties and therapeutic use. *Drugs* 1986, 31, 96–130. [CrossRef]

23. Burgess, D.S.; Hastings, R.W. Activity of piperacillin/tazobactam in combination with amikacin, ciprofloxacin, and trovafloxacin against *Pseudomonas aeruginosa* by time-kill. *Diagn. Microbiol. Infect. Dis.* 2000, 38, 37–41. [CrossRef]

24. Chen, Y.H.; Peng, C.F.; Lu, P.L.; Tsai, J.J.; Chen, T.P. In vitro activities of antibiotic combinations against clinical isolates of *Pseudomonas aeruginosa*. *Kaohsiung J. Med. Sci.* 2004, 20, 261–267. [CrossRef]

25. Fujimura, S.; Takane, H.; Nakano, Y.; Watanabe, A. In vitro synergy studies based on tazobactam/piperacillin against clinical isolates of metallo-beta-lactamase-producing *Pseudomonas aeruginosa*. *J. Antimicrob. Chemother.* 2009, 64, 1115–1116. [CrossRef] [PubMed]

26. El-Sayed Ahmed, M.A.E.; Zhong, L.L.; Shen, C.; Yang, Y.; Doi, Y.; Tian, G.B. Colistin and its role in the Era of antibiotic resistance: An extended review (2000–2019). *Emerg. Microbes Infect.* 2020, 9, 868–885. [CrossRef] [PubMed]

27. Clinical and Laboratory Standards Institute (CLSI). *Performance Standards for Antimicrobial Susceptibility Testing*, 30th ed.; CLSI supplement M100; Clinical and Laboratory Standards Institute: Wayne, PA, USA, 2020.

28. Khosravi, A.D.; Hoveizavi, H.; Momhammad, A.; Farahani, A.; Jenabi, A. Genotyping of multidrug-resistant strains of *Pseudomonas aeruginosa* isolated from burn and wound infections by ERIC–PCR. *Acta Cir. Bras.* 2016, 31, 206–211. [CrossRef] [PubMed]
29. Zarei, O.; Shokoohizadeh, L.; Hosseinpour, H.; Alikhani, M.Y. Molecular analysis of *Pseudomonas aeruginosa* isolated from clinical, environmental and cockroach sources by ERIC–PCR. *BMC Res. Notes* **2018**, *11*, 668. [CrossRef] [PubMed]

30. Preechachuawong, P.; Santimaleeworagun, W.; Jitwasinkul, T.; Samret, W. Detection of new Delhi metallo-beta-lactamase-1-producing *Klebsiella pneumoniae* at a general hospital in Thailand. *Southeast Asian J. Trop. Med. Public Health* **2015**, *46*, 1031–1036.

31. Liu, Y.Y.; Wang, Y.; Walsh, T.R.; Yi, L.X.; Zhang, R.; Spencer, J.; Doi, Y.; Tian, G.; Dong, B.; Huang, X.; et al. Emergence of plasmid-mediated colistin resistance mechanism MCR-1 in animals and human beings in China: A microbiological and molecular biological study. *Lancet Infect. Dis.* **2016**, *16*, 161–168. [CrossRef]

32. Lertsrisatit, Y.; Santimaleeworagun, W.; Thunyaharn, S.; Traipattanakul, J. In vitro activity of colistin mono- and combination therapy against colistin-resistant *Acinetobacter baumannii*, mechanism of resistance, and clinical outcomes of patients infected with colistin-resistant *A. baumannii* at a Thai university hospital. *Infect. Drug Resist.* **2017**, *10*, 437–443. [CrossRef]

33. Peter-Getzlaff, S.; Polsfuss, S.; Poledica, M.; Hombach, M.; Giger, J.; Böttger, E.C.; Zbinden, R.; Bloemberg, G.V. Detection of AmpC beta-lactamase in *Escherichia coli*: Comparison of three phenotypic confirmation assays and genetic analysis. *J. Clin. Microbiol.* **2011**, *49*, 2924–2932. [CrossRef]

34. Kırmusaoğlu, S. The Methods for Detection of Biofilm and Screening Antibiofilm Activity of Agents. In *Antimicrobials, Antibiotic Resistance, Antibiofilm Strategies and Activity Methods*; IntechOpen: London, UK, 2019.

35. Redelman, C.; Marrs, K.; Anderson, G. Discovering Biofilms: Inquiry-Based Activities for the Classroom. *Am. Biol. Teach.* **2012**, *74*, 305–309. [CrossRef]

36. Zaborina, O.; Kohler, J.E.; Wang, Y.; Bethel, C.; Shevchenko, O.; Wu, L.; Turner, J.R.; Alverdy, J.C. Identification of multi-drug resistant *Pseudomonas aeruginosa* clinical isolates that are highly disruptive to the intestinal epithelial barrier. *Ann. Clin. Microbiol. Antimicrob.* **2006**, *5*, 14. [CrossRef] [PubMed]

© 2020 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (http://creativecommons.org/licenses/by/4.0/).